|
1
|
Cheng TY, Cramb SM, Baade PD, Youlden DR,
Nwogu C and Reid ME: The international epidemiology of lung cancer:
Latest trends, disparities, and tumor characteristics. J Thorac
Oncol. 11:1653–1671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD: Pathology of lung cancer. Clin
Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al KEYNOTE-024 Investigators: Pembrolizumab versus
chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl
J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sandler AB, Schiller JH, Gray R, Dimery I,
Brahmer J, Samant M, Wang LI and Johnson DH: Retrospective
evaluation of the clinical and radiographic risk factors associated
with severe pulmonary hemorrhage in first-line advanced,
unresectable non-small-cell lung cancer treated with Carboplatin
and Paclitaxel plus bevacizumab. J Clin Oncol. 27:1405–1412. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in
chemotherapy-naive patients with advanced-stage non-small-cell lung
cancer. J Clin Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paz-Ares L, Tan EH, O'Byrne K, Zhang L,
Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, et al: Afatinib
versus gefitinib in patients with EGFR mutation-positive advanced
non-small-cell lung cancer: Overall survival data from the phase
IIb LUX-Lung 7 trial. Ann Oncol. 28:270–277. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beermann J, Piccoli MT, Viereck J and Thum
T: Non-coding RNAs in development and disease: Background,
mechanisms, and therapeutic approaches. Physiol Rev. 96:1297–1325.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wiemer EA: The role of microRNAs in
cancer: No small matter. Eur J Cancer. 43:1529–1544. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mataki H, Enokida H, Chiyomaru T, Mizuno
K, Matsushita R, Goto Y, Nishikawa R, Higashimoto I, Samukawa T,
Nakagawa M, et al: Downregulation of the microRNA-1/133a cluster
enhances cancer cell migration and invasion in lung-squamous cell
carcinoma via regulation of Coronin1C. J Hum Genet. 60:53–61. 2015.
View Article : Google Scholar
|
|
13
|
Kamikawaji K, Seki N, Watanabe M, Mataki
H, Kumamoto T, Takagi K, Mizuno K and Inoue H: Regulation of LOXL2
and SERPINH1 by antitumor microRNA-29a in lung cancer with
idiopathic pulmonary fibrosis. J Hum Genet. 61:985–993. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mizuno K, Seki N, Mataki H, Matsushita R,
Kamikawaji K, Kumamoto T, Takagi K, Goto Y, Nishikawa R, Kato M, et
al: Tumor-suppressive microRNA-29 family inhibits cancer cell
migration and invasion directly targeting LOXL2 in lung squamous
cell carcinoma. Int J Oncol. 48:450–460. 2016. View Article : Google Scholar :
|
|
15
|
Mataki H, Seki N, Mizuno K, Nohata N,
Kamikawaji K, Kumamoto T, Koshizuka K, Goto Y and Inoue H:
Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and
miR-145-3p) coordinately targeted MTDH in lung squamous cell
carcinoma. Oncotarget. 7:72084–72098. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mataki H, Seki N, Chiyomaru T, Enokida H,
Goto Y, Kumamoto T, Machida K, Mizuno K, Nakagawa M and Inoue H:
Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR
oncogenic signaling in lung squamous cell carcinoma. Int J Oncol.
46:1039–1050. 2015. View Article : Google Scholar
|
|
17
|
Fukumoto I, Kikkawa N, Matsushita R, Kato
M, Kurozumi A, Nishikawa R, Goto Y, Koshizuka K, Hanazawa T,
Enokida H, et al: Tumor-suppressive microRNAs (miR-26a/b,
miR-29a/b/c and miR-218) concertedly suppressed
metastasis-promoting LOXL2 in head and neck squamous cell
carcinoma. J Hum Genet. 61:109–118. 2016. View Article : Google Scholar
|
|
18
|
Kurozumi A, Kato M, Goto Y, Matsushita R,
Nishikawa R, Okato A, Fukumoto I, Ichikawa T and Seki N: Regulation
of the collagen cross-linking enzymes LOXL2 and PLOD2 by
tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int J
Oncol. 48:1837–1846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Koshizuka K, Nohata N, Hanazawa T, Kikkawa
N, Arai T, Okato A, Fukumoto I, Katada K, Okamoto Y and Seki N:
Deep sequencing-based microRNA expression signatures in head and
neck squamous cell carcinoma: Dual strands of pre-miR-150 as
antitumor miRNAs. Oncotarget. 8:30288–30304. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goto Y, Kurozumi A, Arai T, Nohata N,
Kojima S, Okato A, Kato M, Yamazaki K, Ishida Y, Naya Y, et al:
Impact of novel miR-145-3p regulatory networks on survival in
patients with castration-resistant prostate cancer. Br J Cancer.
117:409–420. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidakaå H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa
M, et al: The microRNA expression signature of bladder cancer by
deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mirsadraee S, Oswal D, Alizadeh Y, Caulo A
and van Beek E Jr: The 7th lung cancer TNM classification and
staging system: Review of the changes and implications. World J
Radiol. 4:128–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koshizuka K, Hanazawa T, Fukumoto I,
Kikkawa N, Matsushita R, Mataki H, Mizuno K, Okamoto Y and Seki N:
Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive
miR-1 and miR-206 in head and neck squamous cell carcinoma. J Hum
Genet. 62:113–121. 2017. View Article : Google Scholar
|
|
24
|
Okato A, Goto Y, Kurozumi A, Kato M,
Kojima S, Matsushita R, Yonemori M, Miyamoto K, Ichikawa T and Seki
N: Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in
prostate cancer. Int J Oncol. 49:111–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kojima S, Chiyomaru T, Kawakami K, Yoshino
H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, et
al: Tumour suppressors miR-1 and miR-133a target the oncogenic
function of purine nucleoside phosphorylase (PNP) in prostate
cancer. Br J Cancer. 106:405–413. 2012. View Article : Google Scholar :
|
|
26
|
Turunen SP, Tatti-Bugaeva O and Lehti K:
Membrane-type matrix metalloproteases as diverse effectors of
cancer progression. Biochim Biophys Acta. 1864(11 Pt A): 1974–1988.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Maione P, Sgambato A, Casaluce F, Sacco
PC, Santabarbara G, Rossi A and Gridelli C: The role of the
antiangiogenetic ramucirumab in the treatment of advanced non small
cell lung cancer. Curr Med Chem. 24:3–13. 2017. View Article : Google Scholar
|
|
28
|
Wang F, Ren X and Zhang X: Role of
microRNA-150 in solid tumors. Oncol Lett. 10:11–16. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K,
Ren G, Su T, Pan Y, Feng B, et al: miR-150 promotes gastric cancer
proliferation by negatively regulating the pro-apoptotic gene EGR2.
Biochem Biophys Res Commun. 392:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang S, Chen Y, Wu W, Ouyang N, Chen J,
Li H, Liu X, Su F, Lin L and Yao Y: miR-150 promotes human breast
cancer growth and malignant behavior by targeting the pro-apoptotic
purinergic P2X7 receptor. PLoS One. 8:e807072013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Okato A, Arai T, Kojima S, Koshizuka K,
Osako Y, Idichi T, Kurozumi A, Goto Y, Kato M, Naya Y, et al: Dual
strands of pre-miR-150 (miR-150-5p and miR-150-3p) act as antitumor
miRNAs targeting SPOCK1 in naïve and castration-resistant prostate
cancer. Int J Oncol. 51:245–256. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Osako Y, Seki N, Koshizuka K, Okato A,
Idichi T, Arai T, Omoto I, Sasaki K, Uchikado Y, Kita Y, et al:
Regulation of SPOCK1 by dual strands of pre-miR-150 inhibit cancer
cell migration and invasion in esophageal squamous cell carcinoma.
J Hum Genet. 62:935–944. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar
|
|
34
|
Gilcrease MZ: Integrin signaling in
epithelial cells. Cancer Lett. 247:1–25. 2007. View Article : Google Scholar
|
|
35
|
Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao
Y, Wang XA, Zhang F, Xiang SS, Li HF, et al: SPOCK1 as a potential
cancer prognostic marker promotes the proliferation and metastasis
of gallbladder cancer cells by activating the PI3K/AKT pathway. Mol
Cancer. 14:122015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim HP, Han SW, Song SH, Jeong EG, Lee MY,
Hwang D, Im SA, Bang YJ and Kim TY: Testican-1-mediated
epithelial-mesenchymal transition signaling confers acquired
resistance to lapatinib in HER2-positive gastric cancer. Oncogene.
33:3334–3341. 2014. View Article : Google Scholar
|
|
37
|
Miao L, Wang Y, Xia H, Yao C, Cai H and
Song Y: SPOCK1 is a novel transforming growth factor-β target gene
that regulates lung cancer cell epithelial-mesenchymal transition.
Biochem Biophys Res Commun. 440:792–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang YZ, Wu KP, Wu AB, Yang ZC, Li JM, Mo
YL, Xu M, Wu B and Yang ZX: MMP-14 overexpression correlates with
poor prognosis in non-small cell lung cancer. Tumour Biol.
35:9815–9821. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lu H, Hu L, Yu L, Wang X, Urvalek AM, Li
T, Shen C, Mukherjee D, Lahiri SK, Wason MS, et al: KLF8 and FAK
cooperatively enrich the active MMP14 on the cell surface required
for the metastatic progression of breast cancer. Oncogene.
33:2909–2917. 2014. View Article : Google Scholar :
|
|
40
|
Hagemann T, Gunawan B, Schulz M, Füzesi L
and Binder C: mRNA expression of matrix metalloproteases and their
inhibitors differs in subtypes of renal cell carcinomas. Eur J
Cancer. 37:1839–1846. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gawden-Bone C, Zhou Z, King E, Prescott A,
Watts C and Lucocq J: Dendritic cell podosomes are protrusive and
invade the extracellular matrix using metalloproteinase MMP-14. J
Cell Sci. 123:1427–1437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gálvez BG, Matías-Román S, Yáñez-Mó M,
Sánchez-Madrid F and Arroyo AG: ECM regulates MT1-MMP localization
with beta1 or alphavbeta3 integrins at distinct cell compartments
modulating its internalization and activity on human endothelial
cells. J Cell Biol. 159:509–521. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Munshi HG and Stack MS: Reciprocal
interactions between adhesion receptor signaling and MMP
regulation. Cancer Metastasis Rev. 25:45–56. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cho SH, Park YS, Kim HJ, Kim CH, Lim SW,
Huh JW, Lee JH and Kim HR: CD44 enhances the epithelial-mesenchymal
transition in association with colon cancer invasion. Int J Oncol.
41:211–218. 2012.PubMed/NCBI
|
|
45
|
Zarrabi K, Dufour A, Li J, Kuscu C,
Pulkoski-Gross A, Zhi J, Hu Y, Sampson NS, Zucker S and Cao J:
Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer
cell migration. J Biol Chem. 286:33167–33177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hojilla CV, Mohammed FF and Khokha R:
Matrix metalloproteinases and their tissue inhibitors direct cell
fate during cancer development. Br J Cancer. 89:1817–1821. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li Y, Kuscu C, Banach A, Zhang Q,
Pulkoski-Gross A, Kim D, Liu J, Roth E, Li E, Shroyer KR, et al:
miR-181a-5p inhibits cancer cell migration and angiogenesis via
downregulation of matrix metalloproteinase-14. Cancer Res.
75:2674–2685. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zuo QF, Cao LY, Yu T, Gong L, Wang LN,
Zhao YL, Xiao B and Zou QM: MicroRNA-22 inhibits tumor growth and
metastasis in gastric cancer by directly targeting MMP14 and Snail.
Cell Death Dis. 6:e20002015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Osako Y, Seki N, Kita Y, Yonemori K,
Koshizuka K, Kurozumi A, Omoto I, Sasaki K, Uchikado Y, Kurahara H,
et al: Regulation of MMP13 by antitumor microRNA-375 markedly
inhibits cancer cell migration and invasion in esophageal squamous
cell carcinoma. Int J Oncol. 49:2255–2264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yonemori M, Seki N, Yoshino H, Matsushita
R, Miyamoto K, Nakagawa M and Enokida H: Dual tumor-suppressors
miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in
bladder cancer. Cancer Sci. 107:1233–1242. 2016. View Article : Google Scholar : PubMed/NCBI
|
